Magazine Article | October 4, 2018

Companies To Watch: Symbiotix Biotherapies

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Targeting inflammation with molecules emerging from the human microbiome.

SNAPSHOT

Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical- stage development of its lead compound, SYMB-104, for treating MS and inflammatory bowel disease (IBD). It has at least six earlier programs underway with SYMB-104 and another candidate, SYMB-202, seeking a variety of indications for inflammatory, autoimmune, and immuno-oncology conditions. Its proprietary Reglemer technology is based on the most well-studied, microbiome-derived molecule to date, now protected by issued composition- of-matter (COM) patents.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: